Paul Tudor Jones’s Anavex Life Sciences AVXL Stock Holding History

Paul Tudor Jones’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.8K	Sell	20,377 -22,331	-52%	-$66.1K	﹤0.01%	3429
2026 Q1	$131K	Buy	+42,708	New	+$185K	﹤0.01%	3438
2025 Q1	–	Sell	-46,044	Closed	-$495K	–	3044
2024 Q4	$495K	Buy	+46,044	New	+$354K	﹤0.01%	2251
2023 Q1	–	Sell	-34,350	Closed	-$318K	–	2394
2022 Q4	$318K	Buy	+34,350	New	+$367K	0.01%	1866
2021 Q3	–	Sell	-33,481	Closed	-$765K	–	2443
2021 Q2	$765K	Buy	+33,481	New	+$496K	0.01%	973
2016 Q4	–	Sell	-20,600	Closed	-$75K	–	1384
2016 Q3	$75K	Buy	+20,600	New	+$86.7K	﹤0.01%	1359

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paul Tudor Jones's AVXL Position: Q2 2026 in Review

Paul Tudor Jones reduced its Anavex Life Sciences (AVXL) stake by 52% in Q2 2026, selling an estimated $66.1K and leaving 20,377 shares worth $52.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

Paul Tudor Jones first reported a position in AVXL in Q3 2016 and has held it in 6 quarters since. The position peaked at $765K in Q2 2021. 177 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Paul Tudor Jones held 20,377 shares of Anavex Life Sciences worth $52.8K as of Q2 2026.
Paul Tudor Jones sold 22,331 Anavex Life Sciences shares in Q2 2026, an estimated $66.1K.
Anavex Life Sciences made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3429 holding.
Paul Tudor Jones first reported a position in Anavex Life Sciences in Q3 2016 and has held it in 6 quarters since.
Paul Tudor Jones's Anavex Life Sciences position peaked at $765K in Q2 2021.
177 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.